PULMATRIX, INC. Reimbursement from Limited Partnership Investment
PULMATRIX, INC. (PULM) reported Reimbursement from Limited Partnership Investment of $2.00 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ReimbursementFromLimitedPartnershipInvestment · last filed 2023-11-09
- PULMATRIX, INC. reimbursement from limited partnership investment for the quarter ending 2023-09-30 was -$300.00K.
- PULMATRIX, INC. reimbursement from limited partnership investment for the quarter ending 2023-06-30 was -$200.00K.
- PULMATRIX, INC. reimbursement from limited partnership investment for the quarter ending 2023-03-31 was $2.50M.
- PULMATRIX, INC. reimbursement from limited partnership investment for the quarter ending 2022-12-31 was $600.00K.
- PULMATRIX, INC. reimbursement from limited partnership investment for fiscal 2022 was $2.50M.
| Period end | Reimbursement from Limited Partnership Investment 3 month | Reimbursement from Limited Partnership Investment 6 month | Reimbursement from Limited Partnership Investment 9 month | Reimbursement from Limited Partnership Investment 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$500.00K derived: sum of 2 quarters · filed 2023-11-09 | $2.00M 10-Q · filed 2023-11-09 | $2.60M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.30M 10-Q · filed 2023-08-10 | $2.90M derived: sum of 3 quarters · filed 2023-08-10 | $2.40M derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $2.50M 10-Q · filed 2023-05-12 | $3.10M derived: sum of 2 quarters · filed 2023-05-12 | $2.60M derived: sum of 3 quarters · filed 2023-05-12 | |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $100.00K derived: sum of 2 quarters · filed 2023-03-30 | $2.50M 10-K · filed 2023-03-30 | |
| 2022-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.90M 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $2.40M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |